BiTEs, CAR T-Cell Therapy, and ADCs Offer Variety of Lymphoma Treatment Options, But Questions Remain

BiTEs, CAR T-Cell Therapy, and ADCs Offer Variety of Lymphoma Treatment Options, But Questions Remain - Blog

Bispecific T-cells (BiTE), CAR T-cell therapies and antibody-drug conjugates (ADCs) have revolutionised the treatment of haematological malignancies. However, accessibility and unexplored clinical issues present challenges for patients and clinicians for optimal integration into treatment regimens. The lowest barrier to access is for ADCs, largely because the institutional set-up for administration would be minimal.  However, for […]